AURX Nuo Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1091596 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY123.7%
TTM net income YoY2.0%
TTM EPS YoY—
Revenue 3-yr CAGR308.7%
Net income 3-yr CAGR—
Margins
Gross margin70.4%
Operating margin-98.3%
Net margin-93.1%
FCF margin-44.6%
EBITDA margin-95.5%
Returns
ROE-1,032.5%
ROA-133.3%
ROIC (approx.)—
Asset turnover1.43x
Leverage & solvency
Liabilities / assets121.8%
Debt / equity—
Current ratio1.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-82.1%
Payout ratio—
Capex / revenue8.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.31M | $1.37M | $608,525 | $112,250 | $0 |
| Cost of revenue | $1.10M | $302,842 | $126,092 | $19,214 | $0 |
| Gross profit | $2.22M | $1.06M | $482,433 | $93,036 | $0 |
| R&D expense | — | — | — | — | $0 |
| SG&A expense | $4.73M | $3.52M | $3.65M | $3.41M | $90,670 |
| Operating income | -$2.52M | -$2.46M | -$3.17M | -$3.32M | -$90,670 |
| Interest expense | — | — | — | — | $0 |
| Pretax income | -$2.51M | -$2.32M | -$3.17M | -$3.17M | -$90,670 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.51M | -$2.32M | -$3.17M | -$3.17M | -$90,670 |
| EBITDA | -$2.43M | -$2.43M | -$3.15M | -$3.31M | -$90,670 |
| EPS (basic) | -0.05 | -0.05 | -0.08 | -0.08 | -0.03 |
| EPS (diluted) | — | — | — | — | -0.03 |
| Weighted avg. shares (diluted) | — | — | — | — | 30.30M |
| Balance sheet | |||||
| Cash & equivalents | $548,946 | $283,714 | $928,681 | $2.05M | $1.41M |
| Receivables | $561,667 | $248,205 | $250,703 | $92,320 | $0 |
| Inventory | $213,761 | $150,442 | $209,589 | $240,005 | $0 |
| Current assets | $1.38M | $841,546 | $1.56M | $2.63M | $1.47M |
| PP&E, net | $366,315 | $177,022 | $45,082 | $53,165 | $0 |
| Total assets | $1.85M | $1.19M | $1.88M | $3.05M | $1.47M |
| Current liabilities | $1.31M | $578,451 | $674,527 | $600,431 | $673,079 |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $0 |
| Total liabilities | $2.80M | $675,796 | $838,732 | $856,022 | $673,079 |
| Shareholders' equity | -$956,559 | $513,712 | $1.04M | $2.19M | $792,839 |
| Net debt | — | — | — | — | -$1.41M |
| Shares outstanding | 48.18M | 46.82M | 44.24M | 41.80M | 37.12M |
| Cash flow statement | |||||
| Operating cash flow | -$864,971 | -$2.23M | -$3.17M | -$3.71M | -$119,955 |
| Capital expenditure | $274,756 | $154,962 | $7,244 | $59,992 | $0 |
| Free cash flow | -$1.14M | -$2.39M | -$3.18M | -$3.77M | -$119,955 |
| Investing cash flow | -$274,756 | -$154,962 | -$7,244 | -$59,992 | $0 |
| Financing cash flow | $1.40M | $1.74M | $2.00M | $4.46M | $1.37M |
| Depreciation & amortization | $85,463 | $23,022 | $15,327 | $6,827 | $0 |
| Stock-based compensation | $85,986 | $56,652 | $21,746 | $9,145 | $13,936 |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.